In vitro and in vivo effects of free and chalcones-loaded nanoemulsions: Insights and challenges in targeted cancer Chemotherapies

International Journal of Environmental Research and Public Health

Volumn 11, Issue 10, 2014, Pages 10016-10035

  Winter, Evelyn ^a   Dal Pizzol, Carine ^a   Locatelli, Claudriana ^b   Silva, Adny H ^a   Conte, Aline ^b   Chiaradia Delatorre, Louise D ^a   Nunes, Ricardo J ^a   Yunes, Rosendo A ^a   Creckzynski Pasa, Tânia B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDADE DO OESTE DE SANTA CATARINA   (Brazil)

Author keywords

Chalcones; Chemotherapy; Leukemia; Nanoemulsion; Nanomedicine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CATALASE; CHALCONE DERIVATIVE; CHOLESTEROL; CREATININE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; PROTEIN; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; UREA; ANTINEOPLASTIC AGENT; EMULSION; NANOPARTICLE;

CANCER; CHEMOTHERAPY; EMULSION; MEDICINE; NANOTECHNOLOGY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; ENCAPSULATION; ENCAPSULATION EFFICIENCY; HEPATOMEGALY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKEMIA CELL LINE; LEUKOCYTE COUNT; LIVER INJURY; MALE; MONONUCLEAR CELL; MOUSE; NANOEMULSION; NEUTROPHIL COUNT; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYDISPERSITY INDEX; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; VERO CELL LINE; WEIGHT REDUCTION; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; DRUG DELIVERY SYSTEM; EMULSION; LEUKEMIA; LEUKEMIA L 1210; LIVER; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CERCOPITHECUS AETHIOPS; CHALCONES; DRUG DELIVERY SYSTEMS; EMULSIONS; IN VITRO TECHNIQUES; LEUKEMIA; LEUKEMIA L1210; LIVER; MALE; MICE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; OXIDATIVE STRESS; VERO CELLS;

EID: 84908341765     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph111010016     Document Type: Article

References (63)

1. 1. Hunger, S.P.; Lu, X.; Devidas, M.; Camitta, B.M.; Gaynon, P.S.; Winick, N.J.; Reaman, G.H.; Carroll, W.L. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children's oncology group. J. Clin. Oncol. 2012, 30, 1663–1669.
2. 2. Diller, L. Adult Primary Care after Childhood Acute Lymphoblastic Leukemia. N. Eng. J. Med. 2011, 365, 1417–1424.
3. 3. Reulen, R.C.; Winter, D.L.; Frobisher, C.; Lancashire, E.R.; Stiller, C.A.; Jenney, M.E.; Skinner, R.; Stevens, M.C.; Hawkins, M.M.; British Childhood Canc, S. Long-term Cause-Specific Mortality Among Survivors of Childhood Cancer. J. Am. Med. Ass. 2010, 304, 172–179.
4. 4. Mertens, A.C.; Liu, Q.; Neglia, J.P.; Wasilewski, K.; Leisenring, W.; Armstrong, G.T.; Robison, L.L.; Yasui, Y. Cause-specific late mortality among 5-year survivors of childhood cancer: The childhood cancer survivor study. J. Nat. Cancer Inst. 2008, 100, 1368–1379.
5. 5. Kaste, S.C.; Rai, S.N.; Fleming, K.; McCammon, E.A.; Tylavsky, F.A.; Danish, R.K.; Rose, S.R.; Sitter, C.D.; Pui, C.H.; Hudson, M.M. Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Ped. Blood Cancer 2006, 46, 77–87.
6. 6. Thomas, I.H.; Donohue, J.E.; Ness, K.K.; Dengel, D.R.; Baker, K.S.; Gurney, J.G. Bone Mineral Density in Young Adult Survivors of Acute Lymphoblastic Leukemia. Cancer 2008, 113, 3248–3256.
7. 7. Pui, C.H. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2003, 21, 179–181.
8. 8. Bassan, R.; Hoelzer, D. Modern therapy of acute lymphoblastic leukemia. J. Clin. Oncol. 2011, 29, 532–543.
9. 9. Sahoo, S.K.; Parveen, S.; Panda, J.J. The present and future of nanotechnology in human health care. Nanomedicine 2007, 3, 20–31.
10. 10. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 2001, 47, 65–81.
11. 11. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Li, Y.; Wu, X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59, 491–504.
12. 12. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O.C. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014, 66, 2–25.
13. 13. Ganta, S.; Talekar, M.; Singh, A.; Coleman, T.P.; Amiji, M.M. Nanoemulsions in Translational Research-Opportunities and Challenges in Targeted Cancer Therapy. AAPS PharmSciTech 2014, 15, 694–708.
14. 14. Gao, F.; Zhang, Z.; Bu, H.; Huang, Y.; Gao, Z.; Shen, J.; Zhao, C.; Li, Y. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. J. Control. Release 2011, 149, 168–174.
15. 15. Winter, E.; Chiaradia, L.D.; de Cordova, C.A.; Nunes, R.J.; Yunes, R.A.; Creczynski-Pasa, T.B. Naphthylchalcones induce apoptosis and caspase activation in a leukemia cell line: The relationship between mitochondrial damage, oxidative stress, and cell death. Bioorg. Med. Chem. 2010, 18, 8026–8034.
16. 16. Winter, E.; Chiaradia, L.D.; Silva, A.H.; Nunes, R.J.; Yunes, R.A.; Creczynski-Pasa, T.B. Involvement of extrinsic and intrinsic apoptotic pathways together with endoplasmic reticulum stress in cell death induced by naphthylchalcones in a leukemic cell line: Advantages of multi-target action. Toxicol. In Vitro 2014, 28, 769–777.
17. 17. Chiaradia, L.D.; Santos, R.; Vitor, C.E.; Vieira, A.A.; Leal, P.C.; Nunes, R.J.; Calixto, J.B.; Yunes, R.A. Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: Quantitative structure—activity relationships. Bioorg. Med. Chem. 2008, 16, 658–667.
18. 18. Fontana, G.; Maniscalco, L.; Schillaci, D.; Cavallaro, G.; Giammona, G. Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv. 2005, 12, 385–392.
19. 19. Chandrasekhar, S. Stochastic Problems in Physics and Astronomy. Rev. Modern Physics 1943, 15, 1–89.
20. ICH Expert Working Group. Validation of Analytical Procedures: Text and Methodology Q2(R1). Available online: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf (accessed on 15 July 2014).
21. 21. Michalowski, C.B.; Guterres, S.S.; Dalla Costa, T. Microdialysis for evaluating the entrapment and release of a lipophilic drug from nanoparticles. J. Pharm. Biomed. Anal. 2004, 35, 1093–1100.
22. 22. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55–63.
23. 23. Morton, D.B.; Jennings, M.; Buckwell, A.; Ewbank, R.; Godfrey, C.; Holgate, B.; Inglis, I.; James, R.; Page, C.; Sharman, I.; et al. Refining procedures for the administration of substances. Report of the BVAAWF/FRAME/RSPCA/UFAW Joint Working Group on Refinement. British Veterinary Association Animal Welfare Foundation/Fund for the Replacement of Animals in Medical Experiments/Royal Society for the Prevention of Cruelty to Animals/Universities Federation for Animal Welfare. Lab. Anim. 2001, 35, 1–41.
24. 24. Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265–275.
25. 25. Cathcart, R.; Schwiers, E.; Ames, B.N. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal. Biochem. 1983, 134, 111–116.
26. 26. Flohe, L.; Gunzler, W.A. Assays of glutathione peroxidase. Methods Enzymol. 1984, 105, 114–121.
27. 27. Aebi, H. Catalase in vitro. Methods Enzymol. 1984, 105, 121–126.
28. 28. Carlberg, I.; Mannervik, B. Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J. Biol. Chem. 1975, 250, 5475–5480.
29. 29. Keen, J.H.; Habig, W.H.; Jakoby, W.B. Mechanism for the several activities of the glutathione S-transferases. J. Biol. Chem. 1976, 251, 6183–6188.
30. 30. Bird, R.P.; Draper, H.H. Comparative studies on different methods of malonaldehyde determination. Methods Enzymol. 1984, 105, 299–305.
31. 31. Beutler, E.; Duron, O.; Kelly, B.M. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 1963, 61, 882–888.
32. 32. Garg, D.K.; Goyal, R.N. Haematological and hepatotoxic effects of silken styles of corn in albino rats. J. Appl. Toxicol. 1992, 12, 359–363.
33. 33. Pari, L.; Murugavel, P. Role of diallyl tetrasulfide in ameliorating the cadmium induced biochemical changes in rats. Environ. Toxicol. Pharmacol. 2005, 20, 493–500.
34. 34. Ahsan, F.; Rivas, I.P.; Khan, M.A.; Torres Suárez, A.I. Targeting to macrophages: Role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J. Control. Rel. 2002, 79, 29–40.
35. 35. Galindo-Rodriguez, S.; Allemann, E.; Fessi, H.; Doelker, E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm. Res. 2004, 21, 1428–1439.
36. 36. Santos, L.; Curi Pedrosa, R.; Correa, R.; Cechinel Filho, V.; Nunes, R.J.; Yunes, R.A. Biological evaluation of chalcones and analogues as hypolipidemic agents. Arch. Pharm. (Weinheim) 2006, 339, 541–546.
37. 37. Sarker, D.K. Engineering of nanoemulsions for drug delivery. Curr. Drug Deliv. 2005, 2, 297–310.
38. 38. Xiang, G.; Wu, J.; Lu, Y.; Liu, Z.; Lee, R.J. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int. J. Pharm. 2008, 356, 29–36.
39. 39. Lu, Y.; Wu, J.; Wu, J.; Gonit, M.; Yang, X.; Lee, A.; Xiang, G.; Li, H.; Liu, S.; Marcucci, G.; et al. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol. Pharm. 2007, 4, 707–712.
40. 40. Salazar, M.D.; Ratnam, M. The folate receptor: What does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 2007, 26, 141–152.
41. 41. Basha, R.; Sabnis, N.; Heym, K.; Bowman, W.P.; Lacko, A.G. Targeted nanoparticles for pediatric leukemia therapy. Front. Oncol. 2014, 4, doi:10.3389/fonc.2014.00101.
42. Satake, N.; Lee, J.; Xiao, K.; Luo, J.; Sarangi, S.; Chang, A.; McLaughlin, B.; Zhou, P.; Kenney, E.; Kraynov, L.; et al. Nanoparticle targeted therapy against childhood acute lymphoblastic leukemia. SPIE 8031, Micro- and Nanotechnology Sensors, Systems, and Applications III 2011, 2011; 80311U1–80311U5.
43. 43. Chen, W.C.; Sigal, D.S.; Saven, A.; Paulson, J.C. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leuk. Lymphoma 2012, 53, 208–210.
44. 44. Chen, W.C.; Completo, G.C.; Sigal, D.S.; Crocker, P.R.; Saven, A.; Paulson, J.C. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 2010, 115, 4778–4786.
45. 45. Krishnan, V.; Xu, X.; Barwe, S.P.; Yang, X.; Czymmek, K.; Waldman, S.A.; Mason, R.W.; Jia, X.; Rajasekaran, A.K. Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: A novel application in pediatric nanomedicine. Mol. Pharm. 2013, 10, 2199–2210.
46. 46. Memisoglu-Bilensoy, E.; Vural, I.; Bochot, A.; Renoir, J.M.; Duchene, D.; Hıncal, A.A. Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles: In vitro characterization and cytotoxicity. J. Control. Rel. 2005, 104, 489–496.
47. 47. Yadav, K.S.; Jacob, S.; Sachdeva, G.; Chuttani, K.; Mishra, A.K.; Sawant, K.K. Long circulating PEGylated PLGA nanoparticles of cytarabine for targeting leukemia. J. Microencapsul. 2011, 28, 729–742.
48. 48. Jin, Y.J.; Termsarasab, U.; Ko, S.H.; Shim, J.S.; Chong, S.; Chung, S.J.; Shim, C.K.; Cho, H.J.; Kim, D.D. Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma. Pharm. Res. 2012, 29, 3443–3454.
49. 49. Jain, V.; Swarnakar, N.K.; Mishra, P.R.; Verma, A.; Kaul, A.; Mishra, A.K.; Jain, N.K. Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers in chemotherapy. Biomaterials 2012, 33, 7206–7220.
50. 50. Wohlfart, S.; Gelperina, S.; Kreuter, J. Transport of drugs across the blood–brain barrier by nanoparticles. J. Control. Rel. 2012, 161, 264–273.
51. 51. Kaur, I.P.; Bhandari, R.; Bhandari, S.; Kakkar, V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Rel. 2008, 127, 97–109.
52. 52. Pui, C.H. Central nervous system disease in acute lymphoblastic leukemia: Prophylaxis and treatment. Hemat. Am. Soc. Hematol. Educ. Program. 2006, 1, 142–146.
53. 53. Ng, K.K.; Lovell, J.F.; Zheng, G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc. Chem. Res. 2011, 44, 1105–1113.
54. 54. Hammel, M.; Laggner, P.; Prassl, R. Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system. Chem. Phys. Lipids 2003, 123, 193–207.
55. 55. Ho, Y.K.; Smith, R.G.; Brown, M.S.; Goldstein, J.L. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 1978, 52, 1099–1114.
56. 56. Teixeira, R.S.; Valduga, C.J.; Benvenutti, L.A.; Schreier, S.; Maranhao, R.C. Delivery of daunorubicin to cancer cells with decreased toxicity by association with a lipidic nanoemulsion that binds to LDL receptors. J. Pharm. Pharmacol. 2008, 60, 1287–1295.
57. 57. Graziani, S.R.; Igreja, F.A.; Hegg, R.; Meneghetti, C.; Brandizzi, L.I.; Barboza, R.; Amancio, R.F.; Pinotti, J.A.; Maranhao, R.C. Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol. Oncol. 2002, 85, 493–497.
58. 58. Dias, M.L.; Carvalho, J.P.; Rodrigues, D.G.; Graziani, S.R.; Maranhao, R.C. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother. Pharmacol. 2007, 59, 105–111.
59. 59. Almeida, C.P.; Vital, C.G.; Contente, T.C.; Maria, D.A.; Maranhao, R.C. Modification of composition of a nanoemulsion with different cholesteryl ester molecular species: Effects on stability, peroxidation, and cell uptake. Int. J. Nanomedicine 2010, 5, 679–686.
60. 60. Versluis, A.J.; van Geel, P.J.; Oppelaar, H.; van Berkel, T.J.; Bijsterbosch, M.K. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br. J. Cancer 1996, 74, 525–532.
61. 61. Landesman-Milo, D.; Peer, D. Altering the immune response with lipid-based nanoparticles. J. Control. Rel. 2012, 161, 600–608.
62. 62. Lopez, A.M.; Hendrickson, R.G. Toxin-Induced hepatic injury. Emerg. Med. Clin. North. Am. 2014, 32, 103–125.
63. 63. Field, K.M.; Dow, C.; Michael, M. Part I: Liver function in oncology: Biochemistry and beyond. Lancet Oncol. 2008, 9, 1092–1101.